Patent 11931375 was granted and assigned to Voyager Therapeutics on March, 2024 by the United States Patent and Trademark Office.
The present disclosure relates to AAVs encoding a SOD1 targeting polynucleotide which may be used to treat amyotrophic lateral sclerosis (ALS) and delivery methods for the treatment of spinal cord related disorders including ALS.